ACE2 expression and activity are enhanced during pregnancy.
In the current study, we investigated the expression and activity of ACE2 during pregnancy in normotensive and hypertensive rats, focusing on the relative contribution of the uterus and the placentas, the kidney serving as a reference. We used the Sabra rat model of salt-sensitive hypertension. We confirmed a systemic vasodilatory state during the third trimester of pregnancy, as evidenced by a reduction in blood pressure, both in normotensive and hypertensive rats. At the time that blood pressure was reduced, ACE2 was expressed abundantly in the reproductive organs. The relative levels of ACE2 mRNA in the pregnant animal were placenta > kidneys > or = uterus and of ACE2 activity kidney > placenta > uterus. In the uterus and the placenta, ACE2 expression was unaffected by strain, salt-loading, or the level of blood pressure. ACE2 activity in the uterus of the nonpregnant rat was not affected by any of these variables either, but during pregnancy increased in salt-loaded animals. When estimating the total contribution of the uterus to ACE2 mRNA and activity during pregnancy, we found that the amount of ACE2 mRNA increased in both strains irrespective of diet, but that ACE2 activity increased only in salt-loaded animals. We further estimated the relative total contribution of the uterus, placentas, and kidneys to ACE2 expression and activity during pregnancy by adjusting for mass and number of organs and found that the placentas were the major contributors, followed by the kidney and the uterus. We conclude that during pregnancy, the placentas, in particular, but also the uterus, constitute important sources of ACE2, in addition to its normal production in the kidney, leading to an estimated twofold increase in total ACE2 activity. These data are consistent the hypothesis that transient ACE2 overexpression and increased activity during pregnancy may be important in modulating systemic, as well as local hemodynamics in the uteroplacental unit.
Levy
Anat
A
Laboratory for Molecular Medicine, Faculty of Health Sciences, Ben-Gurion University, Barzilai Medical Center Campus, Ashkelon 78306, Israel.
Yagil
Yoram
Y
Bursztyn
Michael
M
Barkalifa
Ronit
R
Scharf
Shimon
S
Yagil
Chana
C
D000085962:Angiotensin-Converting Enzyme 2; D000818:Animals; D001794:Blood Pressure; D004195:Disease Models, Animal; D005260:Female; D006973:Hypertension / Q000201:enzymology* / Q000209:etiology / Q000503:physiopathology; D046110:Hypertension, Pregnancy-Induced / Q000201:enzymology* / Q000209:etiology / Q000503:physiopathology; D007668:Kidney / Q000201:enzymology*; D007703:Peptidyl-Dipeptidase A / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D010920:Placenta / Q000201:enzymology*; D011247:Pregnancy; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D017673:Sodium Chloride, Dietary; D013045:Species Specificity; D013997:Time Factors; D015854:Up-Regulation; D014599:Uterus / Q000201:enzymology*
D012333:RNA, Messenger; D017673:Sodium Chloride, Dietary; D007703:Peptidyl-Dipeptidase A; C000705329:Ace2 protein, rat; D000085962:Angiotensin-Converting Enzyme 2